BEZ235 and the JAK2 inhibitor ruxolitinib have synergistic activity against JAK2V617F mutated cell lines, haematopoietic progenitors from JAK2V617F KI mice and MPN patients. Here, JAK2 is linked to myeloproliferative disorder.